EUCTR2007-001666-32-GB进行中（未招募）不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR, CD20-POSITIVE B-CELL NON-HODGKIN’S LYMPHOMA THAT HAS PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •>Signed Informed Consent Form
- •> Age =18 years
- •>Diagnosis of follicular, CD20-positive B-cell NHL classified as Grade 1, 2, or
- •3a according to the WHO classification of malignant lymphomas
- •>Progression of disease after an objective response (CR/CRu or PR) or SD according to revised IWG criteria lasting 6 months following completion of the most recent rituximab-containing regimen
- •>A rituximab-containing regimen is defined as rituximab as a single agent
- •during induction and/or maintenance, or in combination with other agents.
- •>Measurable disease (according to modified IWG Criteria; see Appendix B)
- •ECOG performance status of 0 or 1 (see Appendix D)
- •>Life expectancy of 3 months
- •>Willingness and capability to be accessible for follow-up until study
- •termination or death
- •>For patients of reproductive potential (both males and females), use of a
- •reliable means of contraception (e.g., contraceptive pill, intrauterine device
- •[IUD], barrier methods) throughout the trial and for 1 year following their last
- •exposure to study treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •>Grade 3b follicular lymphoma (according to the WHO classification) or
- •histologic transformation from follicular lymphoma to aggressive lymphoma
- •>Prior radiotherapy to a lesion(s) that will be used to assess response unless
- •that lesion(s) shows clear evidence of lymphoma progression at baseline
- •(i.e., =50% increase in the product of the longest perpendicular diameters of
- •the lesion [greatest transverse diameter perpendicular diameter] when
- •compared with the nadir of lesion dimensions following radiotherapy and
- •1.5 cm in the greatest transverse diameter)
- •>Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or
- •radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to
- •Cycle 1, Day 1
- •> Patients who received prior radio-immunotherapy for relapsed or refractory follicular NHL at least 1 year prior to first administration of study drug (i.e, rituximab) may participate if they meet minimal study requirements for peripheral blood counts (see below) and do not demonstrate evidence of myelodyplastic syndrome (MDS) on their screening bone marrow biopsy (as evidenced by cytogenetic or FISH criteria).
- •>Concurrent systemic corticosteroid therapy (except low-dose corticosteroid
- •therapy used to treat an illness other than lymphoma or single doses of up to 100mg hydrocortisone, administered as prophylaxis against rituximab-mediated infusion reactions)
- •>Other invasive malignancies within 3 years prior to first study drug administration (i.e, rituximab) except for adequately treated (with curative intent) basal or squamous cell skin cancer,in situ carcinoma of the cervix, in situ breast cancer, in situ prostate cancer, limited-stage bladder cancer, or other cancers from which the patient has been disease-free for at least three years.
- •>History or evidence on physical examination of central nervous system
- •(CNS) disease (e.g., primary brain tumor, CNS lymphoma, seizures not
- •controlled with standard medical therapy, any brain metastases, or history
- •>Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL
- •>General Medical Concerns
- •>Current or recent (within the 28 days prior to Cycle 1, Day 1) participation in
- •another experimental drug study
- •>Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,
- •myocardial infarction within 1 year prior to Cycle 1, Day 1, unstable angina),
- •New York Heart Association (NYHA; see Appendix E) Grade II or greater
- •congestive heart failure, serious cardiac arrhythmia requiring medication
- •within 1 year prior to Cycle1, Day 1, or Grade II or greater peripheral vascular
- •disease (see Appendix F) at study entry
- •>Active infection requiring parenteral antibiotics on Cycle 1, Day 1
- •Protocol: Apomab—Genentech,
- •>Major surgical procedure (excluding lymph node biopsy) or significant
- •traumatic injury within 28 days prior to Cycle 1, Day 1, or anticipation of need
- •for major surgical procedure during the course of the study
- •>Pregnancy (positive pregnancy test) or breast feeding
- •>Serious, non-healing wound, ulcer, or bone fracture
- •Laboratory values
- •ANC 1500/L (may not be treated with G-CSF to maintain or exceed
- •this level) Platelet count 75,000/L Total bilirubin1.6 mg/dL AST or ALT 2.5 the upper limit of normal (ULN) Serum creatinine 2.0 mg/dL or measured creatinine clearance
- •=50 mL/min Hemoglobin 9 g/dL (may not be transfused or treated with erythropoietin to maintain or exceed this level)
- •>Known human immunodeficiency virus (HIV) infection, seropositivi
研究者
相似试验
未知
不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, STUDY TO ASSESS THEEFFICACY AND SAFETY OF LEBRIKIZUMAB INPATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS-J631 Bauxite fibrosis (of lung)-J633 Graphite fibrosis (of lung)Bauxite fibrosis (of lung)Graphite fibrosis (of lung)J631J633PER-083-13F. HOFFMANN-LA ROCHE LTD.,
进行中（未招募）
1 期
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR, CD20-POSITIVE B-CELL NON-HODGKIN’S LYMPHOMA THAT HAS PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPYESTUDIO FASE II, ALEATORIZADO , DOBLE CIEGO, CONTROLADO CON PLACEBO PARA VALORAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE MULTIPLES DOSIS DE APOMAB ADMINISTRADAS POR VIA INTRAVENOSA EN COMBINACIÓN CON RITUXIMAB EN PACIENTES CON LINFOMA NON HODGKING FOLICULAR CON CELULAS B CD20 POSITIVAS QUE HAN PROGRESADO DESPUÉS DE UNA TERAPIA PREVIA CON RITUXIMABFollicular, CD20-Positive B-Cell Non-Hodgkin's LymphomaLinfoma Non-Hodgking folicular con céluas B CD20 positivasMedDRA version: 9.1Level: LLTClassification code 10029593Term: Non-Hodgkin's lymphoma NOSEUCTR2007-001666-32-ESGenentech Inc80
招募中
不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATETHE SAFETY AND EFFICACY OF M2951 IN SUBJECTS WITHSYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-M32 Systemic lupus erythematosusM32Systemic lupus erythematosusPER-004-17A43
尚未招募
不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, STUDY TO ASSESS THEEFFICACY AND SAFETY OF LEBRIKIZUMABIN PATIENTS WITH IDIOPATHIC PULMONARYFIBROSIS-J631 Bauxite fibrosis (of lung)-J633 Graphite fibrosis (of lung)Bauxite fibrosis (of lung)Graphite fibrosis (of lung)J631J633PER-045-15F. HOFFMANN-LA ROCHE LTD.,7
进行中（未招募）
1 期
Safety and efficacy of Cemdisiran in athypical hemolytic uremic syndromeMedDRA version: 20.0Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 100000004851Atypical Hemolytic Uremic SyndromeEUCTR2018-004382-13-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI